[SCHEDULE 13G] Ironwood Pharmaceuticals, Inc. - SEC Filing

Rhea-AI Filing Summary

Barclays PLC reports beneficial ownership of 11,133,857 shares of Ironwood Pharmaceuticals common stock, representing 6.88% of the class. The statement shows Barclays has sole voting and dispositive power over these shares and indicates the securities are held in the ordinary course of business and were not acquired to change or influence control. The filing names Barclays Bank PLC, Barclays Capital Inc. and Barclays Capital Securities Ltd. as relevant subsidiaries associated with the reported holdings.

Positive

• Material ownership disclosed: 11,133,857 shares representing 6.88% of Ironwood common stock.
• Sole voting and dispositive power: Barclays reports exclusive voting and disposition authority over the reported shares.

Negative

• None.

Insights

Financial Analyst

TL;DR: Barclays holds a material 6.88% stake with sole voting and dispositive power.

The filing discloses a beneficial position of 11,133,857 Ironwood shares (6.88%), with Barclays stating sole voting and dispositive power for that amount. The certification affirms the shares are held in the ordinary course and were not acquired to influence control, which frames this as a declared passive stake. The disclosure is material because it exceeds 5% and centralizes authority over those shares within Barclays and identified subsidiaries.

Corporate Governance Expert

TL;DR: A significant ownership stake is reported but certified as not intended to change control.

Barclays' schedule shows centralized control of a meaningful equity stake through sole voting and dispositive rights for 11,133,857 shares. The filing explicitly states the position is held in the ordinary course and not to change or influence the issuer's control. The filing also identifies Barclays Bank PLC, Barclays Capital Inc and Barclays Capital Securities Ltd. as related entities tied to the acquisition and classification.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

IRONWOOD PHARMACEUTICALS INC

(Name of Issuer)

COMMON-STOCK

(Title of Class of Securities)

46333X108

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 46333X108

1

Names of Reporting Persons

Barclays PLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 11,133,857.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 11,133,857.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,133,857.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.88 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: IRONWOOD PHARMACEUTICALS INC
(b)	Address of issuer's principal executive offices: 100 Summer Street, Suite 2300, MA, 02110
Item 2.
(a)	Name of person filing: Barclays PLC
(b)	Address or principal business office or, if none, residence: 1 Churchill Place, London - E14 5HP
(c)	Citizenship: X0
(d)	Title of class of securities: COMMON-STOCK
(e)	CUSIP No.: 46333X108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 11133857
(b)	Percent of class: 6.88 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 11133857
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 11133857
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Barclays PLC

Signature:	Ramya Rao
Name/Title:	Director
Date:	08/12/2025

FAQ

Who filed the Schedule 13G for Ironwood (IRWD)?

The filing was submitted by Barclays PLC.

How many Ironwood shares does Barclays beneficially own?

Barclays beneficially owns 11,133,857 shares of Ironwood common stock.

What percentage of Ironwood does Barclays' holding represent?

The reported stake represents 6.88% of the common stock class.

Does Barclays have voting or dispositive power over the shares?

Yes. The filing reports sole voting and sole dispositive power for the 11,133,857 shares.

Is the stake intended to influence control of Ironwood?

The filing includes a certification that the securities are held in the ordinary course of business and were not acquired to change or influence control.